Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 39


Molecular Insights of Pathways Resulting From Two Common PIK3CA Mutations in Breast Cancer.

Bhat-Nakshatri P, Goswami CP, Badve S, Magnani L, Lupien M, Nakshatri H.

Cancer Res. 2016 Apr 25. pii: canres.3174.2015. [Epub ahead of print]


Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization.

Nakshatri H, Anjanappa M, Bhat-Nakshatri P.

Sci Rep. 2015 Aug 27;5:13526. doi: 10.1038/srep13526.


Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells.

Burnett RM, Craven KE, Krishnamurthy P, Goswami CP, Badve S, Crooks P, Mathews WP, Bhat-Nakshatri P, Nakshatri H.

Oncotarget. 2015 May 20;6(14):12682-96.


NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT.

Nakshatri H, Appaiah HN, Anjanappa M, Gilley D, Tanaka H, Badve S, Crooks PA, Mathews W, Sweeney C, Bhat-Nakshatri P.

Cell Death Dis. 2015 Jan 22;6:e1608. doi: 10.1038/cddis.2014.569.


Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle.

Chen D, Goswami CP, Burnett RM, Anjanappa M, Bhat-Nakshatri P, Muller W, Nakshatri H.

Cancer Res. 2014 Aug 15;74(16):4270-81. doi: 10.1158/0008-5472.CAN-13-2817. Epub 2014 Jun 30.


Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity.

Bhat-Nakshatri P, Goswami CP, Badve S, Sledge GW Jr, Nakshatri H.

Sci Rep. 2013;3:2530. doi: 10.1038/srep02530.


ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer.

Chen D, Bhat-Nakshatri P, Goswami C, Badve S, Nakshatri H.

Cancer Res. 2013 Sep 15;73(18):5821-33. doi: 10.1158/0008-5472.CAN-13-1080. Epub 2013 Jul 5.


Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing.

Bhat-Nakshatri P, Song EK, Collins NR, Uversky VN, Dunker AK, O'Malley BW, Geistlinger TR, Carroll JS, Brown M, Nakshatri H.

BMC Med Genomics. 2013 Jun 11;6:21. doi: 10.1186/1755-8794-6-21.


Control of EVI-1 oncogene expression in metastatic breast cancer cells through microRNA miR-22.

Patel JB, Appaiah HN, Burnett RM, Bhat-Nakshatri P, Wang G, Mehta R, Badve S, Thomson MJ, Hammond S, Steeg P, Liu Y, Nakshatri H.

Oncogene. 2011 Mar 17;30(11):1290-301. doi: 10.1038/onc.2010.510. Epub 2010 Nov 8.


SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44+/CD24- phenotype.

Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet R Jr, Badve S, Srour EF, Nakshatri H.

BMC Cancer. 2010 Aug 6;10:411. doi: 10.1186/1471-2407-10-411.


ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer.

Appaiah H, Bhat-Nakshatri P, Mehta R, Thorat M, Badve S, Nakshatri H.

Cancer Biol Ther. 2010 Sep 15;10(6):600-14. Epub 2010 Sep 4.


Subcellular localization of activated AKT in estrogen receptor- and progesterone receptor-expressing breast cancers: potential clinical implications.

Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H.

Am J Pathol. 2010 May;176(5):2139-49. doi: 10.2353/ajpath.2010.090477. Epub 2010 Mar 12.


Prognosis of hormone-dependent breast cancers: implications of the presence of dysfunctional transcriptional networks activated by insulin via the immune transcription factor T-bet.

McCune K, Bhat-Nakshatri P, Thorat MA, Nephew KP, Badve S, Nakshatri H.

Cancer Res. 2010 Jan 15;70(2):685-96. doi: 10.1158/0008-5472.CAN-09-1530. Epub 2010 Jan 12.


Estradiol-regulated microRNAs control estradiol response in breast cancer cells.

Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown M, Hammond S, Srour EF, Liu Y, Nakshatri H.

Nucleic Acids Res. 2009 Aug;37(14):4850-61. doi: 10.1093/nar/gkp500. Epub 2009 Jun 14.


NF-kappaB inhibition in human hepatocellular carcinoma and its potential as adjunct to sorafenib based therapy.

Wu JM, Sheng H, Saxena R, Skill NJ, Bhat-Nakshatri P, Yu M, Nakshatri H, Maluccio MA.

Cancer Lett. 2009 Jun 18;278(2):145-55. doi: 10.1016/j.canlet.2008.12.031. Epub 2009 Mar 20.


AKT alters genome-wide estrogen receptor alpha binding and impacts estrogen signaling in breast cancer.

Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M, Badve S, Liu Y, Nakshatri H.

Mol Cell Biol. 2008 Dec;28(24):7487-503. doi: 10.1128/MCB.00799-08. Epub 2008 Oct 6.


Negative regulation of chemokine receptor CXCR4 by tumor suppressor p53 in breast cancer cells: implications of p53 mutation or isoform expression on breast cancer cell invasion.

Mehta SA, Christopherson KW, Bhat-Nakshatri P, Goulet RJ Jr, Broxmeyer HE, Kopelovich L, Nakshatri H.

Oncogene. 2007 May 17;26(23):3329-37. Epub 2006 Nov 27.


CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis.

Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R Jr, Badve S, Nakshatri H.

Breast Cancer Res. 2006;8(5):R59.


Restoring chemotherapy and hormone therapy sensitivity by parthenolide in a xenograft hormone refractory prostate cancer model.

Shanmugam R, Jayaprakasan V, Gokmen-Polar Y, Kelich S, Miller KD, Yip-Schneider M, Cheng L, Bhat-Nakshatri P, Sledge GW Jr, Nakshatri H, Zheng QH, Miller MA, DeGrado T, Hutchins GD, Sweeney CJ.

Prostate. 2006 Oct 1;66(14):1498-511.


Negative regulation of MHC class II gene expression by CXCR4.

Sheridan C, Sadaria M, Bhat-Nakshatri P, Goulet R Jr, Edenberg HJ, McCarthy BP, Chang CH, Srour EF, Nakshatri H.

Exp Hematol. 2006 Aug;34(8):1085-92.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk